Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lercanidipine
Drug ID BADD_D01255
Description Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Indications and Usage For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
Marketing Status approved; investigational
ATC Code C08CA13
DrugBank ID DB00528
KEGG ID D08111
MeSH ID C060343
PubChem ID 65866
TTD Drug ID D0P6ZH
NDC Product Code Not Available
UNII V7XTJ4R0BH
Synonyms lercanidipine | methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | lercanidipine hydrochloride | Zanidip | Lerdip | Lercadip | REC 15-2375 | REC-15-2375
Chemical Information
Molecular Formula C36H41N3O6
CAS Registry Number 100427-26-7
SMILES CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+ ](=O)[O-])C(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.004--Not Available
Dry mouth07.06.01.002--
Dry throat22.12.03.005; 07.06.01.005--Not Available
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dysphonia22.12.03.006; 19.19.03.002; 17.02.08.004--
Dyspnoea02.11.05.003; 22.02.01.004--
Ear disorder04.03.01.001--Not Available
Eosinophilic pneumonia22.01.01.004; 01.02.04.003--Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.009--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gamma-glutamyltransferase increased13.03.04.024--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Gingival hypertrophy07.09.13.008--Not Available
Glossitis07.14.01.001--Not Available
Gynaecomastia05.05.02.003; 21.05.04.003--
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages